Substrate reduction therapy for inborn errors of metabolism.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Inborn errors of metabolism (IEM) are monogenic disorders caused by enzyme defects, leading to biochemical abnormalities.
• Despite genetic understanding, effective therapies for many IEMs are lacking, posing significant burdens.
• Current treatments are often ineffective or costly, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in substrate reduction therapy (SRT) for inborn errors of metabolism.
• To focus on drug repurposing, novel target validation, and gene silencing for IEM therapeutic development.

Main Methods:

• Literature review of emerging SRT approaches.
• Analysis of pre-clinical and clinical applications of SRT.
• Exploration of drug repurposing, target validation, and gene silencing strategies.

Main Results:

• SRT emerges as a promising therapeutic approach for IEMs by targeting substrate accumulation.
• Repurposing approved drugs, validating new targets, and screening for molecules are key strategies.
• Gene silencing presents an emerging therapeutic modality for IEMs.

Conclusions:

• SRT offers a viable strategy for managing IEMs by addressing toxic substrate accumulation.
• Continued research into drug repurposing, target identification, and gene silencing is crucial for developing effective IEM therapies.